期刊
EUROPEAN JOURNAL OF IMMUNOLOGY
卷 43, 期 8, 页码 1995-2002出版社
WILEY
DOI: 10.1002/eji.201343632
关键词
Drug therapy complications; HIV-1 infection; Immune reconstitution inflammatory syndrome; Tuberculosis
类别
资金
- MRC [U1175.02.002.00014.01]
- Wellcome Trust [084323, 088316, 098316]
- European Union [PIRSES-GA-2011-295214]
- Medical Research Council [MC_U117588499] Funding Source: researchfish
- MRC [MC_U117588499] Funding Source: UKRI
HIV-1 patients co-infected with some pathogens are at risk of developing the immune reconstitution inflammatory syndrome (IRIS) when initiating antiretroviral therapy (ART). IRIS is characterized by inflammation leading to the clinical worsening of a treated infection or the unmasking of a previously undiagnosed condition or infection. It is commonly associated with tuberculosis (TB), 8-43% of the HIV-TB co-infected patients prescribed with antitubercular treatment and ART develop TB-IRIS. Although IRIS has been recognized for over 20 years, relatively little was known until recently about its pathogenesis. Despite these advances in understanding IRIS, there remains no immune biomarker for diagnostic or prognostic purposes. Here, we review the risk factors associated with TB-IRIS, the challenges in studying this syndrome, and how Tlymphocytes, dysregulated cytokine responses, and innate immunity may contribute to the development of TB-IRIS.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据